Meta-analysis of naltrexone and acamprosate for treating alcohol use disorders: When are these medications most helpful?

Addiction

Volumn 108, Issue 2, 2013, Pages 275-293

  Maisel, Natalya C ^a   Blodgett, Janet C ^a   Wilbourne, Paula L ^a   Humphreys, Keith ^a,b   Finney, John W ^a,b  

^a VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Acamprosate; Alcohol use disorders; Meta analysis; Naltrexone; Pharmacotherapy; Treatment

Indexed keywords

ACAMPROSATE; ALCOHOL; DRUG DERIVATIVE; DRUGS USED IN THE TREATMENT OF ADDICTION; NALTREXONE; NARCOTIC ANTAGONIST; TAURINE;

ALCOHOLISM; COMPARATIVE STUDY; DRUG DETOXIFICATION; HUMAN; META ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TIME; TREATMENT OUTCOME; ALCOHOL-RELATED DISORDERS; ANALOGS AND DERIVATIVES; DRUG INACTIVATION;

ALCOHOL DETERRENTS; ALCOHOL-RELATED DISORDERS; ETHANOL; HUMANS; METABOLIC DETOXICATION, DRUG; NALTREXONE; NARCOTIC ANTAGONISTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TAURINE; TIME FACTORS; TREATMENT OUTCOME; INACTIVATION, METABOLIC;

EID: 84872605970     PISSN: 09652140     EISSN: 13600443     Source Type: Journal    
DOI: 10.1111/j.1360-0443.2012.04054.x     Document Type: Article

References (82)

1. Department of Veterans Affairs and Department of Defense. VA/DoD Clinical Practice Guideline for Management of Substance Use Disorders (SUD). Washington, DC: Department of Veterans Affairs and Department of Defense; 2009.
2. American Psychiatric Association, Physician Consortium for Performance Improvement, National Committee for Quality Assurance. Substance Use Disorders Performance Measurement Set. Chicago: American Medical Association; National Committee for Quality Assurance; 2008.
3. National Institute for Health and Clinical Excellence (NICE). Alcohol Use Disorders: Diagnosis, Assessment and Management of Harmful Drinking and Alcohol Dependence. London: NICE; 2011.
4. Substance Abuse and Mental Health Services Administration. The N-SSATS Report: Services Provided by Substance Abuse Treatment Facilities in the United States. Rockville, MD: Office of Applied Studies; 2009.
5. Roman P. M., Abraham A. J., Knudsen H. K. Using medication-assisted treatment for substance use disorders: evidence of barriers and facilitators of implementation. Addict Behav 2011; 36: 584-589.
6. Harris A. H., Kivlahan D. R., Bowe T., Humphreys K. N. Pharmacotherapy of alcohol use disorders in the Veterans Health Administration. Psychiatr Serv 2010; 61: 392-398.
7. Garbutt J. C., West S. L., Carey T. S., Lohr K. N., Crews F. T. Pharmacological treatment of alcohol dependence: a review of the evidence. JAMA 1999; 281: 1318-1325.
8. Bouza C., Angeles M., Munoz A., Amate J. M. Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: a systematic review. Addiction 2004; 99: 811-828.
9. Kranzler H. R., Van Kirk J. Efficacy of naltrexone and acamprosate for alcoholism treatment: a meta-analysis. Alcohol Clin Exp Res 2001; 25: 1335-1341.
10. Mann K., Lehert P., Morgan M. Y. The efficacy of acamprosate in the maintenance of abstinence in alcohol-dependent individuals: results of a meta-analysis. Alcohol Clin Exp Res 2004; 28: 51-63.
11. Rosner S., Hackl-Herrwerth A., Leucht S., Lehert P., Vecchi S., Soyka M. Acamprosate for alcohol dependence. Cochrane Database Syst Rev 2010; 9: CD004332.
12. Rosner S., Hackl-Herrwerth A., Leucht S., Vecchi S., Srisurapanont M., Soyka M. Opioid antagonists for alcohol dependence. Cochrane Database Syst Rev 2010; 12: CD001867.
13. Rosner S., Leucht S., Lehert P., Soyka M. Acamprosate supports abstinence, naltrexone prevents excessive drinking: evidence from a meta-analysis with unreported outcomes. J Psychopharmacol 2008; 22: 11-23.
14. Snyder J. L., Bowers T. G. The efficacy of acamprosate and naltrexone in the treatment of alcohol dependence: a relative benefits analysis of randomized controlled trials. Am J Drug Alcohol Abuse 2008; 34: 449-461.
15. Mason B. J., Goodman A. M., Dixon R. M., Hameed M. H. A., Hulot T., Wesnes K. etal. A pharmacokinetic and pharmacodynamic drug interaction study of acamprosate and naltrexone. Neuropsychopharmacology 2002; 27: 596-606.
16. Ray L. A., Chin P. F., Miotto K. Naltrexone for the treatment of alcoholism: clinical findings, mechanisms of action, and pharmacogenetics. CNS Neurol Disord Drug Targets 2010; 9: 13-22.
17. Pettinati H. M., O'Brien C. P., Rabinowitz A. R., Wortman S. P., Oslin D. W., Kampman K. M. etal. The status of naltrexone in the treatment of alcohol dependence: specific effects on heavy drinking. J Clin Psychopharmacol 2006; 26: 610-625.
18. Kennedy W. K., Leloux M., Kutscher E. C., Price P. L., Morstad A. E., Carnahan R. M. Acamprosate. Expert Opin Drug Metab Toxicol 2010; 6: 363-380.
19. Richardson K., Baillie A., Reid S., Morley K., Teesson M., Sannibale C. etal. Do acamprosate or naltrexone have an effect on daily drinking by reducing craving for alcohol? Addiction 2008; 103: 953-959.
20. Mason B. J. Acamprosate for alcohol dependence: an update for the clinician. Focus 2006; 4: 505-511.
21. Kazdin A. E. Evidence-based treatment and practice: new opportunities to bridge clinical research and practice, enhance the knowledge base, and improve patient care. Am Psychol 2008; 63: 146-159.
22. Abraham A. J., Ducharme L. J., Roman P. M. Counselor attitudes toward pharmacotherapies for alcohol dependence. J Stud Alcohol Drugs 2009; 70: 628-635.
23. Soyka M., Chick J. Use of acamprosate and opioid antagonists in the treatment of alcohol dependence: a European perspective. Am J Addict 2003; 12: S69-80.
24. Sinclair J. D. Evidence about the use of naltrexone and for different ways of using it in the treatment of alcoholism. Alcohol Alcohol 2001; 36: 2-10.
25. Heinala P., Alho H., Kiianmaa K., Lonnqvist J., Kuoppasalmi K., Sinclair J. D. Targeted use of naltrexone without prior detoxification in the treatment of alcohol dependence: a factorial double-blind, placebo-controlled trial. J Clin Psychopharmacol 2001; 21: 287-292.
26. O'Malley S. S., Sinha R., Grilo C. M., Capone C., Farren C. K., McKee S. A. etal. Naltrexone and cognitive behavioral coping skills therapy for the treatment of alcohol drinking and eating disorder features in alcohol-dependent women: a randomized controlled trial. Alcohol Clin Exp Res 2007; 31: 625-634.
27. Garbutt J. C., Kranzler H. R., O'Malley S. S., Gastfriend D. R., Pettinati H. M., Silverman B. L. etal. Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial. JAMA 2005; 293: 1617-1625.
28. Overman G. P., Teter C. J., Guthrie S. K. Acamprosate for the adjunctive treatment of alcohol dependence. Ann Pharmacother 2003; 37: 1090-1099.
29. Kranzler H. R., Gage A. Acamprosate efficacy in alcohol-dependent patients: summary of results from three pivotal trials. Am J Addict 2008; 17: 70-76.
30. Kampman K. M., Pettinati H. M., Lynch K. G., Xie H., Dackis C., Oslin D. W. etal. Initiating acamprosate within-detoxification versus post-detoxification in the treatment of alcohol dependence. Addict Behav 2009; 34: 581-586.
31. Garbutt J. C. Efficacy and tolerability of naltrexone in the management of alcohol dependence. Curr Pharm Des 2010; 16: 2091-2097.
32. Mason B. J., Crean R. Acamprosate in the treatment of alcohol dependence: clinical and economic considerations. Expert Rev Neurother 2007; 7: 1465-1477.
33. Anton R. F. Naltrexone for the management of alcohol dependence. N Engl J Med 2008; 359: 715-721.
34. Anton R. F., Moak D. H., Latham P. K. The obsessive compulsive drinking scale: a new method of assessing outcome in alcoholism treatment studies. Arch Gen Psychiatry 1996; 53: 225-231.
35. Potgieter A. S., Deckers F., Geerlings P. Craving and relapse measurement in alcoholism. Alcohol Alcohol 1999; 34: 254-260.
36. Cohen J. Statistical Power Analysis for the Behavioral Sciences, 2nd edn. Hillsdale, NJ: Lawrence Erlbaum; 1988.
37. Shadish W., Robinson L., Lu C. ES: A computer program and manual for effect size calculation [computer software and manual]. Version 1.0. St. Paul, MN: Assessment Systems Corporation; 1999. p. 221-233.
38. Borenstein M. Effect sizes for continuous data. In: Cooper H., Hedges L. V., Valentine J. C., editors. The Handbook of Research Synthesis and Meta-Analysis, 2nd edn. New York: Russell Sage Foundation; 2009, p. 221-235.
39. Hedges L. V., Olkin I. Statistical Methods for Meta-Analysis. New York: Academic Press; 1985.
40. Haddock C. K., Rindskopf D., Shadish W. R. Using odds ratios as effect sizes for meta-analysis of dichotomous data: a primer on methods and issues. Psychol Methods 1998; 3: 339-353.
41. Shadish W. R., Haddock C. K. Combining estimates of effect size. In: Cooper H., Hedges L. V., Valentine J. C., editors. The Handbook of Research Synthesis and Meta-Analysis, 2nd edn. New York: Russell Sage Foundation; 2009, p. 257-277.
42. Wampold B. E., Mondin G. W., Moody M., Stich F., Benson K., Ahn H. A meta-analysis of outcome studies comparing bona fide psychotherapies: empiricially, 'all must have prizes. Psychol Bull 1997; 122: 203-215.
43. Webb G. R., Redman S., Gibberd R. W., Sanson-Fisher R. W. The reliability and stability of a quantity-frequency method and a diary method of measuring alcohol consumption. Drug Alcohol Depend 1991; 27: 223-231.
44. Rosenthal R. Writing meta-analytic reviews. Psychol Bull 1995; 118: 183-192.
45. Gleser L., Olkin I. Stochastically dependent effect sizes. In: Cooper H., Hedges L. V., Valentine J. C., editors. The Handbook of Research Synthesis and Meta-Analysis, 2nd edn. New York: Russell Sage Foundation; 2009, p. 357-376.
46. Borenstein M., Hedges L. V., Higgins J. P. T., Rothstein H. R. Introduction to Meta-Analysis. Chichester: John Wiley & Sons; 2009.
47. R Development Core Team. R: a language and environment for statistical computing [computer software]. Vienna; 2011.
48. Del Re A., Hoyt W. T. MAd: meta-analysis with mean differences (R package) [computer software]. Version 0.4. 2010.
49. Del Re A. RcmdrPlugin.MAd: meta-analysis with mean differences (MAd) Rcmdr Plug-in (R package) [computer software]. Version 1.0.8. 2010.
50. Cisler R. A., Zweben A. Development of a composite measure for assessing alcohol treatment outcome: operationalization and validation. Alcohol Clin Exp Res 1999; 23: 263-271.
51. Raudenbush S. Analyzing effect sizes: random-effects models. In: Cooper H., Hedges L. V., Valentine J. C., editors. The Handbook of Research Synthesis and Meta-Analysis, 2nd edn. New York: Russell Sage Foundation; 2009, p. 295-315.
52. Higgins J. P., Thompson S. G., Deeks J. J., Altman D. G. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557-560.
53. Cuijpers P., van Straten A., Bohlmeijer E., Hollon S. D., Andersson G. The effects of psychotherapy for adult depression are overestimated: a meta-analysis of study quality and effect size. Psychol Med 2009; 40: 211-223.
54. Lipsey M. W., Wilson D. B. Practical Meta-Analysis. Thousand Oaks, CA: Sage Publications; 2001.
55. Overton R. C. A comparison of fixed-effects and mixed (random-effects) models for meta-analysis tests of moderator variable effects. Psychol Methods 1998; 3: 354-379.
56. Viechtbauer W. Metafor. Meta-Analysis Package for R [computer software]. Version 1.6-0. 2011.
57. Rosenthal R. The file drawer problem and tolerance for null results. Psychol Bull 1979; 86: 638-641.
58. Duval S., Tweedie R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 2000; 56: 455-463.
59. Egger M., Smith G. D., Schneider M., Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629-634.
60. Anton R. F., O'Malley S. S., Ciraulo D. A., Cisler R. A., Couper D., Donovan D. M. etal. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA 2006; 295: 2003-2017.
61. Kranzler H. R., Armeli S., Tennen H., Blomqvist O., Oncken C., Petry N. etal. Targeted naltrexone for early problem drinkers. J Clin Psychopharmacol 2003; 23: 294-304.
62. Kranzler H. R., Tennen H., Armeli S., Chan G., Covault J., Arias A. etal. Targeted naltrexone for problem drinkers. J Clin Psychopharmacol 2009; 29: 350-357.
63. O'Malley S. S., Rounsaville B. J., Farren C., Namkoong K., Wu R., Robinson J. etal. Initial and maintenance naltrexone treatment for alcohol dependence using primary care vs specialty care: a nested sequence of 3 randomized trials. Arch Intern Med 2003; 163: 1695-1704.
64. Davidson D., Wirtz P. W., Gulliver S. B., Longabaugh R. Naltrexone's suppressant effects on drinking are limited to the first 3 months of treatment. Psychopharmacology (Berl) 2007; 194: 1-10.
65. O'Malley S. S., Robin R. W., Levenson A. L., GreyWolf I., Chance L. E., Hodgkinson C. A. etal. Naltrexone alone and with sertraline for the treatment of alcohol dependence in Alaska natives and non-natives residing in rural settings: a randomized controlled trial. Alcohol Clin Exp Res 2008; 32: 1271-1283.
66. Morris P. L., Hopwood M., Whelan G., Gardiner J., Drummond E. Naltrexone for alcohol dependence: a randomized controlled trial. Addiction 2001; 96: 1565-1573.
67. Galarza N., Diaz Ramirez D., Guzman F., Caballero J., Martinez A. The use of naltrexone to treat ambulatory patients with alcohol dependence. Bol Asoc Med P R 1997; 89: 157-160.
68. Knox P. C., Donovan D. M. Using naltrexone in inpatient alcoholism treatment. J Psychoactive Drugs 1999; 31: 373-388.
69. Lee A., Tan S., Lim D., Winslow R. M., Wong K. E., Allen J. etal. Naltrexone in the treatment of male alcoholics-an effectiveness study in Singapore. Drug Alcohol Rev 2001; 20: 193-199.
70. Huang M. C., Chen C. H., Yu J. M., Chen C. C. A double-blind, placebo-controlled study of naltrexone in the treatment of alcohol dependence in Taiwan. Addict Biol 2005; 10: 289-292.
71. Budzynski J., Rybakowski J., Swiatkowski M., Torlinski L., Klopocka M., Kosmowski W. etal. Naltrexone exerts a favourable effect on plasma lipids in abstinent patients with alcohol dependence. Alcohol Alcohol 2000; 35: 91-97.
72. Kiefer F., Jahn H., Tarnaske T., Helwig H., Briken P., Holzbach R. etal. Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism: a double-blind, placebo-controlled study. Arch Gen Psychiatry 2003; 60: 92-99.
73. Morley K. C., Teesson M., Reid S. C., Sannibale C., Thomson C., Phung N. etal. Naltrexone versus acamprosate in the treatment of alcohol dependence: a multi-centre, randomized, double-blind, placebo-controlled trial. Addiction 2006; 101: 1451-1462.
74. O'Malley S. S., Garbutt J. C., Gastfriend D. R., Dong Q., Kranzler H. R. Efficacy of extended-release naltrexone in alcohol-dependent patients who are abstinent before treatment. J Clin Psychopharmacol 2007; 27: 507-512.
75. Swift R., Oslin D., Alexander M., Forman R. Adherence monitoring in naltrexone pharmacotherapy trials: a systematic review. J Stud Alcohol Drugs 2011; 72: 1012-1018.
76. Center for Substance Abuse Treatment. Acamprosate: A new medication for alcohol use disorders. Substance Abuse Treatment Advisory 2005; 4.
77. Sterne J. A. C., Egger M., Smith G. D. Investigating and dealing with publication and other biases in meta-analysis. BMJ 2001; 323: 101-105.
78. Thompson S. G., Higgins J. How should meta regression analyses be undertaken and interpreted? Stat Med 2002; 21: 1559-1573.
79. Anton R. F., Moak D. H., Latham P., Waid L. R., Myrick H., Voronin K. etal. Naltrexone combined with either cognitive behavioral or motivational enhancement therapy for alcohol dependence. J Clin Psychopharmacol 2005; 25: 349-357.
80. Substance Abuse and Mental Health Services Administration. Results fromm the 2009 National Survey on Drug Use and Health: volume I. Summary of national findings. Rockville, MD: Office of Applied Studies; 2010.
81. O'Connor P. G., Nyquist J. G., McLellan A. T. Integrating addiction medicine into graduate medical education in primary care: the time has come. Ann Intern Med 2011; 154: 56-59.
82. Harwood H. Updating estimates of the economic costs of alcohol abuse in the United States: estimates, update methods, and data. Report prepared by the Lewing Group for the National Institute on Alcohol Abuse and Alcoholism. 2000.